Followers | 833 |
Posts | 119940 |
Boards Moderated | 17 |
Alias Born | 09/05/2002 |
Friday, October 29, 2021 6:55:29 PM
https://finance.yahoo.com/news/u-food-drug-administration-approves-213100317.html
The drug works by narrowing the pupil, which improves near focusing. It takes effect in 15 minutes and continues working for approximately 6 hours. The purpose is to avoid having to use reading glasses. I project modest sales.
The drug itself is an old generic, but the formulation is new:
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Recent ABBV News
- AbbVie Acquires Celsius Therapeutics • PR Newswire (US) • 06/27/2024 01:26:00 PM
- Introducing Allē Payment Plans, Powered by Cherry • PR Newswire (US) • 06/27/2024 12:30:00 PM
- U.S. Food and Drug Administration Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma • PR Newswire (US) • 06/26/2024 11:03:00 PM
- AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) • PR Newswire (US) • 06/25/2024 12:15:00 PM
- AbbVie Declares Quarterly Dividend • PR Newswire (US) • 06/21/2024 12:00:00 PM
- AbbVie Appoints Roxanne S. Austin as Lead Independent Director of the Board of Directors • PR Newswire (US) • 06/20/2024 12:00:00 PM
- U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease • PR Newswire (US) • 06/18/2024 10:18:00 PM
- AbbVie Recommends Shareholders Reject Tutanota's "Mini-Tender" Offer • PR Newswire (US) • 06/14/2024 08:08:00 PM
- AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease • PR Newswire (US) • 06/13/2024 11:59:00 AM
- BOTOX® Cosmetic (onabotulinumtoxinA) Reveals 2024 Women Entrepreneur Grant Recipients • PR Newswire (US) • 06/11/2024 12:00:00 PM
- AbbVie Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRα) Expressing Platinum-Sensitive Ovarian Cancer • PR Newswire (US) • 06/06/2024 12:45:00 PM
- SkinMedica® Celebrates 25 Years of Empowering Radiant Skin • PR Newswire (US) • 06/06/2024 12:30:00 PM
- AbbVie Launches First-of-its-Kind Contest to Empower People Living with Migraine in their Careers • PR Newswire (US) • 06/06/2024 12:00:00 PM
- AbbVie Advances Oncology Pipeline With Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383 • PR Newswire (US) • 06/05/2024 01:00:00 PM
- RINVOQ® (upadacitinib) Now Available for Pediatric Patients Two Years and Older with Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis • PR Newswire (US) • 06/04/2024 12:30:00 PM
- Refer Your Friends to Allē, the Loyalty Rewards Program by Allergan Aesthetics, and Earn $50 • PR Newswire (US) • 06/04/2024 12:05:00 PM
- AbbVie to Present at the Goldman Sachs 45th Annual Global Healthcare Conference • PR Newswire (US) • 06/03/2024 12:30:00 PM
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/31/2024 08:05:10 PM
- AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis • PR Newswire (US) • 05/31/2024 06:00:00 AM
- AbbVie Showcases Robust Solid Tumor Pipeline at ASCO 2024 with New Data from Its Innovative Antibody-Drug Conjugate (ADC) Platform • PR Newswire (US) • 05/28/2024 12:00:00 PM
- AbbVie Completes Acquisition of Landos Biopharma • PR Newswire (US) • 05/23/2024 08:05:00 PM
- AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week® • PR Newswire (US) • 05/17/2024 11:30:00 AM
- AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders • PR Newswire (US) • 05/13/2024 12:39:00 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/08/2024 09:00:46 PM
- QULIPTA(MC) (atogépant) est maintenant approuvé par Santé Canada pour la prévention de la migraine chronique chez les adultes • PR Newswire (Canada) • 05/08/2024 12:00:00 PM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM